Department of HPB and Transplant Surgery, Freeman Hospital, Newcastle Upon Tyne, Tyne and Wear, United Kingdom.
Institute of Cellular Medicine, Newcastle University, Newcastle Upon Tyne, Tyne and Wear, United Kingdom.
Cancer. 2021 Apr 15;127(8):1266-1274. doi: 10.1002/cncr.33356. Epub 2020 Dec 15.
No convincing evidence for the benefit of adjuvant radiotherapy (RT) following resection of distal cholangiocarcinoma (dCCA) exists, especially for lower-risk (margin- or node-negative) disease. Hence, the association of adjuvant RT on survival after surgical resection of dCCA was compared with no adjuvant RT (noRT).
Using National Cancer Database data from 2004 to 2016, patients undergoing pancreatoduodenectomy for nonmetastatic dCCA were identified. Patients with neoadjuvant RT and chemotherapy and survival <6 months were excluded. Propensity score matching was used to account for treatment-selection bias. A multivariable Cox proportional hazards model was then used to analyze the association of adjuvant RT with survival.
Of 2162 (34%) adjuvant RT and 4155 (66%) noRT patients, 1509 adjuvant RT and 1509 noRT patients remained in the cohort after matching. The rates of node-negative disease (N0), node-positive disease (N+), and unknown node status (Nx) were 39%, 51%, and 10%, respectively. After matching, adjuvant RT was associated with improved survival (median, 29.3 vs 26.8 months; P < .001), which remained after multivariable adjustment (HR, 0.86; 95% CI, 0.80-0.93; P < .001). Multivariable interaction analyses showed this benefit was seen irrespective of nodal status (N0: HR, 0.77; 95% CI, 0.66-0.89; P < .001; N+: HR, 0.79; 95% CI, 0.71-0.89; P < .001) and margin status (R0: HR, 0.58; 95% CI, 0.50-0.67; P < .001; R1: HR, 0.87; 95% CI, 0.78-0.96; P = .007). Stratified analyses by nodal and margin status demonstrated consistent results.
Adjuvant RT after dCCA resection was associated with a survival benefit in patients, even in patients with margin- or node-negative resections. Adjuvant RT should be considered routinely irrespective of margin and nodal status after resection for dCCA.
Adjuvant radiotherapy after resection of distal cholangiocarcinoma was associated with a survival benefit in patients, even in patients with margin-negative or node-negative resections. Adjuvant radiotherapy should be considered routinely irrespective of margin and nodal status after resection of distal cholangiocarcinoma.
对于远端胆管癌(dCCA)切除术后辅助放疗(RT)的获益,尚无令人信服的证据,尤其是对于低风险(切缘或淋巴结阴性)疾病。因此,比较了手术切除 dCCA 后辅助 RT 与无辅助 RT(noRT)的生存情况。
利用 2004 年至 2016 年国家癌症数据库的数据,确定了接受胰十二指肠切除术治疗非转移性 dCCA 的患者。排除了接受新辅助 RT 和化疗且生存时间<6 个月的患者。采用倾向评分匹配来纠正治疗选择偏倚。然后,使用多变量 Cox 比例风险模型分析辅助 RT 与生存的关系。
在 2162 例(34%)接受辅助 RT 和 4155 例(66%)未接受 RT 的患者中,1509 例接受辅助 RT 和 1509 例未接受 RT 的患者在匹配后仍留在队列中。无淋巴结转移(N0)、淋巴结转移(N+)和淋巴结状态未知(Nx)的患者比例分别为 39%、51%和 10%。匹配后,辅助 RT 可改善生存(中位,29.3 与 26.8 个月;P<0.001),多变量调整后仍有此获益(HR,0.86;95%CI,0.80-0.93;P<0.001)。多变量交互分析显示,这种获益与淋巴结状态(N0:HR,0.77;95%CI,0.66-0.89;P<0.001;N+:HR,0.79;95%CI,0.71-0.89;P<0.001)和切缘状态(R0:HR,0.58;95%CI,0.50-0.67;P<0.001;R1:HR,0.87;95%CI,0.78-0.96;P=0.007)无关。按淋巴结和切缘状态分层分析得到了一致的结果。
即使在切缘或淋巴结阴性的患者中,dCCA 切除术后辅助 RT 也与生存获益相关。对于 dCCA 的切除,无论切缘和淋巴结状态如何,都应常规考虑辅助 RT。
该研究旨在探讨辅助放疗(RT)在远端胆管癌(dCCA)切除术后的生存获益。研究使用了国家癌症数据库的数据,并采用倾向评分匹配和多变量 Cox 比例风险模型进行分析。结果表明,辅助 RT 与接受 RT 患者的生存改善相关,且在淋巴结状态和切缘状态不同的患者中均观察到了这种获益。因此,该研究建议对于 dCCA 的切除,无论切缘和淋巴结状态如何,都应常规考虑辅助 RT。
请注意,这只是对研究内容的简要总结,具体的临床决策还需要综合考虑患者的个体情况、治疗目标和医生的专业判断。